Last 35 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Elanco Animal Health Incorporated's quarterly P/E stands at 54.4x, up 169.3% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 57.4% YoY to 12.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -51.07 | 54.39 | — | — | 160.81 | 20.19 | — | 5.03 | — | 63.10 | — | — | — |
| — | +169.3% | — | — | — | -68.0% | — | — | — | +463.9% | — | — | — | |
| P/S Ratio | 2.54 | 2.21 | 2.46 | 2.20 | 1.44 | 1.10 | 1.47 | 1.77 | 1.51 | 1.68 | 1.77 | 1.30 | 1.17 |
| — | +101.1% | +67.5% | +24.0% | -4.5% | -34.4% | -17.3% | +36.9% | +28.5% | +81.8% | +17.4% | -12.2% | -42.5% | |
| P/B Ratio | 1.82 | 1.86 | 1.72 | 1.48 | 1.05 | 0.82 | 0.98 | 1.12 | 1.20 | 1.33 | 1.18 | 0.90 | 0.67 |
| — | +125.8% | +74.9% | +32.3% | -12.2% | -38.1% | -16.8% | +24.1% | +79.7% | +115.3% | +44.1% | +0.5% | -50.3% | |
| P/FCF | 42.21 | — | 61.11 | 19.70 | 9.92 | — | 12.07 | 15.23 | 10.74 | — | 15.82 | 8.39 | 65.20 |
| — | — | +406.3% | +29.3% | -7.6% | — | -23.7% | +81.5% | -83.5% | — | — | -20.8% | +659.0% | |
| EV / EBITDA | 16.59 | 12.76 | 19.06 | 16.66 | 10.64 | 8.11 | 14.30 | 16.94 | 11.18 | 11.28 | 17.63 | 12.88 | 11.58 |
| — | +57.4% | +33.3% | -1.7% | -4.8% | -28.1% | -18.9% | +31.5% | -3.4% | +72.1% | +20.6% | -2.8% | -7.0% | |
| EV / EBIT | 61.35 | — | — | 1690.57 | 28.45 | 20.24 | 223.64 | 4.34 | 93.87 | 43.25 | — | — | 110.94 |
| — | — | — | +38858.9% | -69.7% | -53.2% | — | — | -15.4% | +194.6% | — | — | +58.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Elanco Animal Health Incorporated's operating margin was 22.4% in Q1 2026, up 20.7 pp QoQ and up 12.2 pp YoY. The trailing four-quarter average of 8.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 22.9% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.5% | 57.3% | 39.3% | 53.4% | 46.5% | 46.6% | 38.1% | 39.3% | 47.1% | 46.2% | 36.8% | 41.3% | 46.1% |
| — | +22.9% | +3.1% | +35.8% | -1.3% | +0.8% | +3.6% | -4.8% | +2.3% | -7.6% | -11.3% | -0.6% | -3.0% | |
| Operating Margin | 5.3% | 22.4% | 1.7% | 2.4% | 6.8% | 10.1% | 0.8% | -0.5% | 9.7% | 11.0% | 1.0% | 3.9% | 5.0% |
| — | +120.8% | +111.8% | +589.2% | -29.5% | -8.1% | -18.8% | -112.3% | +93.7% | -37.2% | -64.6% | -19.3% | -55.7% | |
| Net Margin | -4.9% | 4.2% | -24.1% | -3.0% | 0.9% | 5.6% | -0.8% | 35.3% | -4.2% | 2.7% | -13.6% | -102.6% | -9.2% |
| — | -26.0% | -2976.1% | -108.5% | +121.0% | +111.5% | +94.2% | +134.4% | +54.0% | -67.6% | -149.3% | -1519.8% | -978.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.7% | 0.9% | -4.2% | -0.5% | 0.2% | 1.1% | -0.1% | 5.8% | -0.8% | 0.5% | -2.3% | -16.2% | -1.3% |
| — | -18.8% | -3174.1% | -108.6% | +120.1% | +106.5% | +94.4% | +136.1% | +36.0% | -62.6% | -196.5% | -1627.3% | -860.2% | |
| ROA | -1.8% | 0.4% | -2.1% | -0.2% | 0.1% | 0.5% | -0.1% | 2.7% | -0.4% | 0.2% | -1.0% | -7.3% | -0.6% |
| — | -18.2% | -3219.4% | -109.3% | +122.9% | +132.5% | +93.7% | +137.0% | +41.4% | -65.8% | -176.9% | -1609.2% | -878.7% | |
| ROIC | 1.9% | 2.3% | 0.1% | 0.2% | 0.6% | 0.9% | 0.1% | -0.0% | 0.8% | 0.9% | 0.1% | 0.3% | 0.3% |
| — | +155.3% | +138.1% | +663.4% | -19.0% | +4.1% | -8.2% | -113.7% | +151.6% | -32.4% | -60.4% | -15.7% | -60.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Elanco Animal Health Incorporated's Debt/EBITDA ratio is 13.0x, down from 20.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 20.5% YoY to 2.16x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.61 | 0.61 | 0.60 | 0.62 | 0.69 | 0.71 | 0.67 | 0.96 | 0.95 | 0.93 | 0.96 | 0.82 |
| — | -11.2% | -13.4% | -10.7% | -35.0% | -27.3% | -23.6% | -30.7% | +16.9% | +18.3% | +15.9% | +10.1% | -3.8% | |
| Debt / EBITDA | 4.31 | 13.00 | 20.81 | 19.82 | 16.57 | 15.59 | 25.12 | 26.41 | 20.49 | 19.28 | 31.90 | 27.48 | 26.36 |
| — | -16.6% | -17.2% | -24.9% | -19.1% | -19.2% | -21.2% | -3.9% | -22.3% | +26.2% | +7.1% | +1.1% | +32.2% | |
| Current Ratio | 2.17 | 2.16 | 2.17 | 2.40 | 2.60 | 2.71 | 2.44 | 2.55 | 2.93 | 3.29 | 2.75 | 2.82 | 2.84 |
| — | -20.5% | -11.4% | -5.8% | -11.3% | -17.5% | -10.9% | -9.6% | +2.9% | +46.2% | +42.5% | +44.1% | +15.1% | |
| Quick Ratio | 1.08 | 1.12 | 1.08 | 1.23 | 1.40 | 1.46 | 1.25 | 1.31 | 1.75 | 1.96 | 1.35 | 1.48 | 1.53 |
| — | -22.9% | -13.6% | -6.5% | -20.3% | -25.6% | -7.4% | -11.4% | +14.6% | +58.3% | +31.7% | +31.8% | +3.6% | |
| Interest Coverage | -0.02 | 5.39 | -1.85 | 0.04 | 1.36 | 2.13 | 0.18 | 7.58 | 0.51 | 1.18 | -0.90 | -14.24 | 0.23 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ELAN stock.
Elanco Animal Health Incorporated's current P/E is -51.1x. The average P/E over the last 2 quarters is 107.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Elanco Animal Health Incorporated's current operating margin is 5.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Elanco Animal Health Incorporated's business trajectory between earnings reports.